Geriatr Gerontol Int:卒中前痴呆对其缺血性卒中的影响

2015-09-06 MedSci MedSci原创

目的:这篇研究的主要目的是确定卒中前痴呆(PSD)是否影响老年缺血性卒中患者的短期功能预后。方法:对老年缺血性卒中患者进行回顾性病例对照研究。应用功能独立测量量表(FIM)对患者入院和出院时进行功能预后评估。应用t检验,卡方检验,多次线性回归以及logistics回归分析数据。结果:急性缺血性卒中患者919名,其中11.5%诊断为PSD。与非PSD患者相比,PSD患者,存活时间较短,女性患者比例较

目的:这篇研究的主要目的是确定卒中前痴呆(PSD)是否影响老年缺血性卒中患者的短期功能预后。

方法:对老年缺血性卒中患者进行回顾性病例对照研究。应用功能独立测量量表(FIM)对患者入院和出院时进行功能预后评估。应用t检验,卡方检验,多次线性回归以及logistics回归分析数据。

结果:急性缺血性卒中患者919名,其中11.5%诊断为PSD。与非PSD患者相比,PSD患者,存活时间较短(尤其是女性患者),简明精神状态检测分数较低。与PSD患者相比,非PSD入院以及出院时,患者总FIM分数、运动FIM分数以及出院时各项FIM得分均较高。运用logistics回归分析确定预测良好预后(出院FIM ≥80)的因素,PSD与出院时患者不良预后密切相关。

结论:研究表明PSD患者与其缺血性卒中入院出院时较低FIM分数相关。然而,在PSD患者和非PSD患者中,日常运动FIM得分没有差异,表明PSD患者仍然需要急性后期康复治疗。

原文出处:

Mizrahi EH, Arad M, Adunsky A. Pre-stroke dementia does not affect the post-acute care functional outcome of old patients with ischemic stroke. Geriatr Gerontol Int. 2015 Sep 3.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1806025, encodeId=618218060257d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jan 26 01:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892673, encodeId=4acc18926e361, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Apr 13 22:54:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021503, encodeId=4c0a20215030f, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 22 18:54:00 CST 2016, time=2016-01-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1806025, encodeId=618218060257d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jan 26 01:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892673, encodeId=4acc18926e361, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Apr 13 22:54:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021503, encodeId=4c0a20215030f, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 22 18:54:00 CST 2016, time=2016-01-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1806025, encodeId=618218060257d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jan 26 01:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892673, encodeId=4acc18926e361, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Apr 13 22:54:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021503, encodeId=4c0a20215030f, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 22 18:54:00 CST 2016, time=2016-01-22, status=1, ipAttribution=)]